Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) will likely be announcing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($1.56) per share and revenue of $3.8940 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Revolution Medicines Price Performance

RVMD opened at $101.83 on Monday. The firm has a market cap of $19.69 billion, a PE ratio of -19.70 and a beta of 1.00. The stock has a 50-day moving average price of $96.62 and a 200-day moving average price of $68.45. Revolution Medicines has a 1 year low of $29.17 and a 1 year high of $124.49. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05.

Insider Buying and Selling at Revolution Medicines

In other news, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $98.00, for a total transaction of $980,000.00. Following the transaction, the chief financial officer owned 108,065 shares in the company, valued at $10,590,370. This trade represents a 8.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark A. Goldsmith sold 60,000 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $75.08, for a total value of $4,504,800.00. Following the completion of the sale, the insider owned 247,863 shares of the company’s stock, valued at $18,609,554.04. This trade represents a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 173,792 shares of company stock worth $15,239,440. 8.20% of the stock is owned by corporate insiders.

Institutional Trading of Revolution Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in shares of Revolution Medicines by 83.1% in the fourth quarter. Invesco Ltd. now owns 367,851 shares of the company’s stock worth $29,299,000 after buying an additional 166,909 shares during the period. Corient Private Wealth LLC purchased a new stake in Revolution Medicines in the 4th quarter worth approximately $215,000. ADAR1 Capital Management LLC raised its stake in Revolution Medicines by 4.3% during the 4th quarter. ADAR1 Capital Management LLC now owns 145,079 shares of the company’s stock worth $11,556,000 after acquiring an additional 5,943 shares during the period. Empowered Funds LLC purchased a new position in Revolution Medicines during the fourth quarter valued at approximately $77,000. Finally, KVP Capital Advisors LP purchased a new position in shares of Revolution Medicines during the 4th quarter valued at $2,190,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wedbush reiterated an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Royal Bank Of Canada began coverage on Revolution Medicines in a research note on Monday, November 3rd. They set an “outperform” rating and a $77.00 target price on the stock. HC Wainwright boosted their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Wolfe Research initiated coverage on Revolution Medicines in a report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price target on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.